PUBLISHER: The Insight Partners | PRODUCT CODE: 1873985
PUBLISHER: The Insight Partners | PRODUCT CODE: 1873985
Anticoagulant Reversal Drugs Market
The Anticoagulant Reversal Drugs Market is anticipated to grow to US$ 2.44 billion by 2031, up from US$ 1.43 billion in 2024, reflecting a compound annual growth rate (CAGR) of 10.08% from 2031 to 2031. The introduction and launch of innovative products are expected to be significant trends in the anticoagulant reversal drugs market.
Analysis of the Anticoagulant Reversal Drugs Market
Recently, the use of anticoagulants has surged for the prevention and treatment of various cardiovascular issues, including pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), thrombosis related to mechanical heart valves, and acute coronary syndromes. However, the extensive use of these medications poses risks of both major and minor bleeding, which can lead to hospital admissions and emergency visits. This risk is heightened when patients are on combination therapies that include both anticoagulants and antiplatelet or dual antiplatelet therapies. Warfarin and aspirin, when used alone, present the highest bleeding risks. Consequently, anticoagulant reversal drugs are essential for mitigating bleeding risks. The increasing prevalence of atrial fibrillation (AFib) and rising stroke incidents are expected to drive the development of new treatments aimed at improving patient outcomes.
Overview of the Anticoagulant Reversal Drugs Market
According to the Centers for Disease Control and Prevention (CDC), over 454,000 hospitalizations related to AFib occur annually in the US, leading to approximately 158,000 deaths. The likelihood of developing AFib increases with age, and high blood pressure, which is also more prevalent in older populations, contributes to about 1 in 5 AFib cases. The growing elderly population is projected to boost the demand for anticoagulant reversal drugs over the next decade.
Strategic Insights
Drivers and Opportunities in the Anticoagulant Reversal Drugs Market
Increasing Incidence of Neurodegenerative Diseases and Speech Disorders
Anticoagulant reversal drugs play a crucial role in managing hemorrhagic strokes by reducing ongoing bleeding and facilitating tissue recovery. The prevalence of strokes is rising, particularly in low- and middle-income countries. The Stroke Awareness Foundation reports that approximately 795,000 people in the US experience a stroke each year, resulting in over 140,000 deaths. Of these, around 40% of stroke-related fatalities occur in men, while 60% are in women. A study published in the Annals of Palliative Medicine (APM) in May 2021 demonstrated that administering a combination of 4-factor prothrombin complex concentrate, fresh frozen plasma, and vitamin K1 to a patient on warfarin who suffered an acute ischemic stroke (AIS) resulted in neurological improvement and successful reversal of coagulation. Thus, the increasing incidence of strokes is a significant driver for the anticoagulant reversal drugs market.
Opportunities from Growing Research Activities in Novel Anticoagulant Reversal Drugs
Rapid advancements in research for new therapeutics to address the rising prevalence of cardiovascular diseases, such as atrial fibrillation, are propelling the growth of the anticoagulant reversal drugs market. There is a continuous demand for innovative treatment options for various cardiovascular conditions. For example, a study titled 'Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages,' published in July 2020 in the Journal of Thrombosis and Haemostasis, assessed the effectiveness of andexanet alfa in treating intracranial hemorrhages (ICH). The rise in research initiatives is enhancing drug discovery efforts and creating lucrative opportunities for market expansion across the sector.
Segmentation Analysis of the Anticoagulant Reversal Drugs Market
The analysis of the anticoagulant reversal drugs market is segmented by product and distribution channel.
- By product, the market is categorized into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment accounted for the largest market share in 2023.
- Regarding distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and others, with hospital pharmacies holding the largest market share in 2023.
Geographical Analysis of the Anticoagulant Reversal Drugs Market
The geographical scope of the anticoagulant reversal drugs market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America leads the anticoagulant reversal drugs market, with the US being the largest market. The growth in this region is primarily driven by the increasing prevalence of cardiovascular diseases such as atrial fibrillation, advancements by market players, and the presence of major companies in the US, which will further accelerate market growth. Additionally, strategic initiatives by market players in the US are expected to enhance market growth. For instance, in June 2023, AstraZeneca submitted full regulatory filings for its Andexxa (andexanet alfa) in the US and EU, progressing from its current conditional approval. Andexxa is designed to rapidly reverse the anticoagulation effects of direct oral FXa inhibitors, and its use is supported by over 15 national and international guidelines across various disciplines. AstraZeneca is now pursuing full label approval in the US.
Scope of the Anticoagulant Reversal Drugs Market Report
Recent Developments in the Anticoagulant Reversal Drugs Market
The anticoagulant reversal drugs market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments in the market for speech and language disorders:
- AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa, a treatment effective for life-threatening or refractory bleeding associated with Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
- Octapharma USA announced the FDA approval of Balfaxar, a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, along with antithrombotic Proteins C and S. Balfaxar is indicated for urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonist (VKA) therapy in adult patients requiring urgent surgery or invasive procedures, helping to restore blood coagulation by replenishing deficient clotting factors caused by warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)
Coverage and Deliverables of the Anticoagulant Reversal Drugs Market Report
The report titled "Anticoagulant Reversal Drugs Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:
- Market size and forecast at global, regional, and country levels for all key market segments included in the scope
- Market dynamics, including drivers, restraints, and key opportunities
- Key future trends
- Detailed PEST/Porter's Five Forces and SWOT analysis
- Global and regional market analysis highlighting key market trends, major players, regulations, and recent developments
- Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
- In-depth company profiles
Table Of Contents
1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 Global Anticoagulant Reversal Drugs Market and By Product
- 1.3.2 Global Anticoagulant Reversal Drugs Market and By Distribution Channel
- 1.3.3 Global Anticoagulant Reversal Drugs Market and By Geography
2. Anticoagulant Reversal Drugs Market and Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Anticoagulant Reversal Drugs Market and Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 North America and PEST Analysis
- 4.2.2 Europe and PEST Analysis
- 4.2.3 Asia Pacific and PEST Analysis
- 4.2.4 Middle East and Africa
- 4.2.5 South and Central America
- 4.3 Expert Opinion
5. Anticoagulant Reversal Drugs Market and Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rise in Prevalence of Atrial Fibrillation (AFib)
- 5.1.2 Increase in Prevalence of Stroke
- 5.2 Market Restraints
- 5.2.1 High Cost of Anticoagulant Reversal Drugs
- 5.3 Market Opportunities
- 5.3.1 Increasing Research Activities on Anticoagulant Reversal Drugs
- 5.4 Future Trends
- 5.4.1 Development and Launch of Innovative Products
- 5.5 Impact Analysis
6. Anticoagulant Reversal Drugs Market and Global Analysis
- 6.1 Global Anticoagulant Reversal Drugs Market Revenue Forecast And Analysis
- 6.2 Global Anticoagulant Reversal Drugs Market, By Geography - Forecast And Analysis
- 6.3 Market Positioning
7. Anticoagulant Reversal Drugs Marketand By Product
- 7.1 Overview
- 7.2 Anticoagulant Reversal Drugs Market Share, by Product, 2024 and 2031 (%)
- 7.3 Prothrombin Complex Concentrates
- 7.3.1 Overview
- 7.3.2 Prothrombin Complex Concentrates: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 7.4 Vitamin K
- 7.4.1 Overview
- 7.4.2 Vitamin K: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 7.5 Protamine
- 7.5.1 Overview
- 7.5.2 Protamine: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 7.6 Tranexamic Acid
- 7.6.1 Overview
- 7.6.2 Tranexamic Acid: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 7.7 Idarucizumab
- 7.7.1 Overview
- 7.7.2 Idarucizumab: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 7.8 Andexxa
- 7.8.1 Overview
- 7.8.2 Andexxa: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
8. Anticoagulant Reversal Drugs Marketand By Distribution Channel
- 8.1 Overview
- 8.2 Anticoagulant Reversal Drugs Market Share, by Distribution Channel, 2024 and 2031 (%)
- 8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
- 8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
9. Anticoagulant Reversal Drugs Market and Geographic Analysis
- 9.1 North America: Anticoagulant Reversal Drugs Market
- 9.1.1 Overview
- 9.1.2 North America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.3 North America: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
- 9.1.4 North America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 9.1.5 North America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.1.6 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.6.1 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.6.2 US: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
- 9.1.6.3 US: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
- 9.1.7 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.7.1 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.7.2 Canada: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
- 9.1.7.3 Canada: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
- 9.1.8 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.8.1 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.8.2 Mexico: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
- 9.1.8.3 Mexico: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
- 9.2 Europe: Anticoagulant Reversal Drugs Market
- 9.2.1 Overview
- 9.2.2 Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.3 Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.4 Europe: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.5 Europe: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.2.6 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.6.1 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.6.2 Germany: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.6.3 Germany: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.7 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.7.1 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.7.2 France: Anticoagulant Reversal Drugs Market, by Productand Revenue and Forecast to 2031 (USD Million)
- 9.2.7.3 France: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.8 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.8.1 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.8.2 UK: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.8.3 UK: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.9 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.9.1 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.9.2 Italy: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.9.3 Italy: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.10 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.10.1 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.10.2 Spain: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.10.3 Spain: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.11 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.11.1 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.11.2 Rest of Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.11.3 Rest of Europe: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3 Asia Pacific: Anticoagulant Reversal Drugs Market
- 9.3.1 Overview
- 9.3.2 Asia Pacific: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (USD Million)
- 9.3.3 Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.4 Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.5 Asia Pacific: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.3.6 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.6.1 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.6.2 China: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.6.3 China: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.7 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.7.1 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.7.2 Japan: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.7.3 Japan: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.8 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.8.1 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.8.2 India: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.8.3 India: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.9 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.9.1 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.9.2 South Korea: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.9.3 South Korea: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.10 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.10.1 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.10.2 Australia: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.10.3 Australia: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.11 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.11.1 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.3.11.2 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.11.3 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4 Middle East and Africa: Anticoagulant Reversal Drugs Market
- 9.4.1 Overview
- 9.4.2 Middle East and Africa: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 9.4.3 Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.4.4 Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4.5 Middle East and Africa: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.4.6 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.6.1 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.6.2 Saudi Arabia Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.4.6.3 Saudi Arabia Anticoagulant Reversal Drugs Market, Type and Revenue and Forecast to 2031 (USD Million)
- 9.4.7 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.7.1 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.7.2 UAE Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.4.7.3 UAE Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4.8 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.8.1 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.8.2 South Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.4.8.3 South Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4.9 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.9.1 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.4.9.2 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.4.9.3 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5 South and Central America: Anticoagulant Reversal Drugs Market
- 9.5.1 Overview
- 9.5.2 South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.3 South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.5.4 South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5.5 South and Central America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.5.6 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.6.1 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.6.2 Brazil: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.5.6.3 Brazil: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5.7 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.7.1 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.7.2 Argentina: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.5.7.3 Argentina: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5.8 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.8.1 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.8.2 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.5.8.3 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
10. Impact of COVID-19 Pandemic on Global Anticoagulant Reversal Drugs Market
- 10.1 North America: Impact Assessment of COVID-19 Pandemic
- 10.2 Europe: Impact Assessment of COVID-19 Pandemic
- 10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
- 10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
- 10.5 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Anticoagulant Reversal Drugs Marketand Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies Done by the Companies in the Market, (%)
- 11.3 Organic Developments
- 11.3.1 Overview
- 11.3.2 Organic Developments Done By Companies
- 11.4 Inorganic Developments
- 11.4.1 Overview
- 11.4.2 Inorganic Developments Done By Companies
12. Company Profiles
- 12.1 Boehringer Ingelheim International GmbH
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Pfizer Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Octapharma AG
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 AMAG PHARMACEUTICALS, INC.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Fresenius Kabi AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 CSL Limited
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 China Biologic Products, Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Grifols, S.A.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Shanghai RAAS Blood Products Co., Ltd.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
- 13.1 Glossary of Terms
